Adrian T Kress
Overview
Explore the profile of Adrian T Kress including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evans M, Smith D, Kress A, Nadeau R, Selig D, Caridha D, et al.
Clin Transl Sci
. 2024 Jul;
17(7):e13876.
PMID: 38963161
Plerixafor is a CXCR4 antagonist approved in 2008 by the FDA for hematopoietic stem cell collection. Subsequently, plerixafor has shown promise as a potential pathogen-agnostic immunomodulator in a variety of...
2.
Kerling D, Clarke S, DeLuca J, Evans M, Kress A, Nadeau R, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242653
Loop diuretics and antibiotics are commonly co-prescribed across many clinical care settings. Loop diuretics may alter antibiotic pharmacokinetics (PK) via several potential drug interactions. A systematic review of the literature...
3.
Vignali J, Pak K, Beverley H, DeLuca J, Downs J, Kress A, et al.
J Xenobiot
. 2023 May;
13(2):218-236.
PMID: 37218811
Selective Androgen Receptor Modulators (SARMs) are not FDA approved, and obtaining SARMs for personal use is illegal. Nevertheless, SARM use is increasingly popular amongst recreational athletes. Recent case reports of...
4.
Selig D, Kress A, Nadeau R, DeLuca J
Antibiotics (Basel)
. 2023 Mar;
12(3).
PMID: 36978312
Introduction: Probability of target attainment (PTA) analysis using Monte Carlo simulations has become a mainstay of dose optimization. We highlight the technical and clinical factors that may affect PTA for...
5.
Selig D, Akers K, Chung K, Kress A, Livezey J, Por E, et al.
Antibiotics (Basel)
. 2022 May;
11(5).
PMID: 35625262
Critical illness caused by burn and sepsis is associated with pathophysiologic changes that may result in the alteration of pharmacokinetics (PK) of antibiotics. However, it is unclear if one mechanism...
6.
Selig D, Reed T, Chung K, Kress A, Stewart I, DeLuca J
Blood Purif
. 2022 May;
52(1):25-31.
PMID: 35526522
Introduction: The Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is a hemoperfusion device that can remove pathogens from central circulation. However, the effect of Seraph 100 on achieving pharmacodynamic...
7.
Selig D, Kress A, Horton I, Livezey J, Sadik E, DeLuca J
J Clin Pharm Ther
. 2022 May;
47(8):1122-1133.
PMID: 35505520
What Is Known And Objective: Osteoarthritis (OA) is a common cause of joint disease and activity limitation in adults. Common therapies to treat OA-related pain are oral and topical non-steroidal...
8.
Selig D, Livezey J, Chin G, DeLuca J, Guillory Ii W, Kress A, et al.
Mil Med
. 2021 Dec;
187(Suppl 1):9-17.
PMID: 34967405
Introduction: Clinical utilization of pharmacogenomics (PGx) testing is highly institutionally dependent, and little information is known about provider practices of PGx testing in the Military Health System (MHS). In this...
9.
Selig D, Brown A, DeLuca J, Kress A, Livezey J, Oliver T, et al.
Pharmacoepidemiol Drug Saf
. 2020 Sep;
29(12):1605-1615.
PMID: 32897626
Purpose: To explore patterns of antimuscarinic medication as a risk factor for type 2 diabetes mellitus (T2DM). Methods: This is a retrospective cohort study of females 18 years or older...
10.
Regules J, Cicatelli S, Bennett J, Paolino K, Twomey P, Moon J, et al.
J Infect Dis
. 2016 Jun;
214(5):762-71.
PMID: 27296848
Background: Three full doses of RTS,S/AS01 malaria vaccine provides partial protection against controlled human malaria parasite infection (CHMI) and natural exposure. Immunization regimens, including a delayed fractional third dose, were...